Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps

OBJECTIVES: To evaluate within‐patient symptom improvement in the dupilumab SINUS‐24/‐52 studies in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT02912468/NCT02898454). METHODS: Patients received dupilumab 300 mg or placebo every 2 weeks for 24 (SINUS‐24) or 52 weeks (SI...

Descripción completa

Detalles Bibliográficos
Autores principales: Gevaert, Philippe, Lee, Stella E, Settipane, Russell A, Wagenmann, Martin, Msihid, Jérôme, Siddiqui, Shahid, Nash, Scott, Jacob‐Nara, Juby A, Khan, Asif H, Kamat, Siddhesh, Chuang, Chien‐Chia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881398/
https://www.ncbi.nlm.nih.gov/pubmed/36721661
http://dx.doi.org/10.1002/cti2.1433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881398/
https://www.ncbi.nlm.nih.gov/pubmed/36721661
http://dx.doi.org/10.1002/cti2.1433

Ejemplares similares